Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892669 | 0.80 | KDM4E (0.36) | KDM4ECYP3A4CA1CA2 | |
| SCHEMBL2894492 | 0.70 | — | — | |
| SCHEMBL28330357 | 0.67 | — | — | |
| SCHEMBL10946746 | 0.65 | FAAH (0.39) | CA2 | |
| SCHEMBL10945368 | 0.65 | FAAH (0.33) | CA2 | |
| SCHEMBL4373553 | 0.65 | FAAH (0.33) | CA1CA2 | |
| SCHEMBL892430 | 0.61 | FAAH (0.36) | CA1CA2 | |
| SCHEMBL1981760 | 0.61 | CA1 (0.35) | CA1 | |
| SCHEMBL24509802 | 0.60 | — | — | |
| SCHEMBL4865 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117241821-B | Pharmaceutical compositions of polypeptide conjugates and methods of use thereof | 北京质肽生物医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-116848243-B | Liquid pharmaceutical compositions of polypeptide conjugates and methods of use thereof | 北京质肽生物医药科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117241821-A | Pharmaceutical compositions of polypeptide conjugates and methods of use thereof | 北京质肽生物医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-116925237-A | Fusion proteins of GLP-1 and GDF15 and conjugates thereof | 北京质肽生物医药科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116848243-A | Liquid pharmaceutical compositions of polypeptide conjugates and methods of use thereof | 北京质肽生物医药科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-115925994-B | Polypeptide conjugates and methods of use | 北京质肽生物医药科技有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-115260313-B | Fusion proteins of GLP-1 and GDF15 and conjugates thereof | 北京质肽生物医药科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20170217996-A1 | Large-scale diastereoselective syntheses of cycloheptadienylsulfones and stereotetrads | PURDUE RESEARCH FOUNDATION (US) | 2017-08-03 | — | — | US | disclosed |
| WO-2016057606-A1 | LARGE-SCALE DIASTEREOSELECTIVE SYNTHESES OF CYCLOHEPTADIENYLSULFONES AND STEREOTETRADS | PURDUE RESEARCH FOUNDATION (US) | 2016-04-14 | — | — | WO | disclosed |
| US-7501535-B2 | Chemical synthons and intermediates | PURDUE RESEARCH FOUNDATION (US) | 2009-03-10 | — | — | US | disclosed |
| JP-2004203755-A | METHOD FOR PRODUCING VITAMIN A INTERMEDIATE | SUMITOMO CHEM CO LTD | 2004-07-22 | — | — | JP | disclosed |
| US-20040138485-A1 | Chemical synthons and intermediates | PURDUE RESEARCH FOUNDATION | 2004-07-15 | — | — | US | disclosed |
| US-6287840-B1 | PEPTIDOMIMETICS; COUPLING, DEBLOCKING; ANTIARTHRITIC, ANTITUMOR, ANTICARCINOGENIC, AND ANTIMETASTASIS AGENTS; MUSCULAR DYSTROPHY, GLOMERULONEPHRITIS, MALARIA, ALZHEIMER*S DISEASE | AXYS PHARMACEUTICALS, INC. | 2001-09-11 | — | — | US | disclosed |
| US-5976858-A | (S)-(E)-3-(4-MORPHOLINE-CARBONYLLEUCYL)AMINO-5-PHENYL-1-PHENYL SULFONYL-1-PENTENE AND OTHERS; ANTIARTHRITIS/ANTITUMOR/ ANTIINFLAMMATORY/ANTIMETASTASIS AGENTS; TREATMENT OF MUSCULAR DYSTROPHY, MALARIA, ALZHEIMER'S AND AUTOIMMUNE DISEASES | ARRIS PHARMACEUTICALS (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0756625-A4 | IRREVERSIBLE CYSTEINE PROTEASE INHIBITORS CONTAINING VINYL GROUPS CONJUGATED TO ELECTRON WITHDRAWING GROUPS | ARRIS PHARM CORP (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0756625-A1 | IRREVERSIBLE CYSTEINE PROTEASE INHIBITORS CONTAINING VINYL GROUPS CONJUGATED TO ELECTRON WITHDRAWING GROUPS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1997-02-05 | — | — | EP | disclosed |
| WO-1995023222-A1 | IRREVERSIBLE CYSTEINE PROTEASE INHIBITORS CONTAINING VINYL GROUPS CONJUGATED TO ELECTRON WITHDRAWING GROUPS | KHEPRI PHARMACEUTICALS, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217996-A1 | Large-scale diastereoselective syntheses of cycloheptadienylsulfones and stereotetrads | DHPS, STS, FDFT1 | KDM4E 1500/4885CYP3A4 1210/4885CA1 1205/4885 |
| US-20040138485-A1 | Chemical synthons and intermediates | STS, TST, CBS | KDM4E 3615/4885CYP3A4 438/4885CA1 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.